eFFECTOR Therapeutics Inc

NASDAQ:EFTR  
1.50
+0.01 (+0.67%)
Products, Regulatory

Effector Therapeutics Reports Positive Interim Results In Zotatifin Phase 1/2 Clinical Trial

Published: 06/05/2022 21:06 GMT
eFFECTOR Therapeutics Inc (EFTR) - Positive Interim Results in Zotatifin (eft226) Phase 1/2 Clinical Trial Showing Safety and Tolerability,.
Two Partial Responses Observed in Heavily Pre-treated Er+ Breast Cancer Patients.
Effector Therapeutics - Treatment Emergent Adverse Events (teaes) Related to Zotatifin Were Mostly Mild, Readily Managed and Reversible.
Anticipate Reporting Topline Data From Our Current Expansion Cohorts by End of 2022.